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Background: The fatty acid amide palmitoylethanolamide (PEA) has been studied extensively for its anti-
inflammatory and neuroprotective actions. The lipidic nature and large particle size of PEA in the native state may
limit its solubility and bioavailability when given orally, however. Micronized formulations of a drug enhance its rate
of dissolution and reduce variability of absorption when orally administered. The present study was thus designed
to evaluate the oral anti-inflammatory efficacy of micronized/ultramicronized versus nonmicronized PEA
formulations.
Methods: Micronized/ultramicronized PEA was produced by the air-jet milling technique, and the various PEA
preparations were subjected to physicochemical characterization to determine particle size distribution and purity. Each
PEA formulation was then assessed for its anti-inflammatory effects when given orally in the carrageenan-induced rat
paw model of inflammation, a well-established paradigm of edema formation and thermal hyperalgesia.
Results: Intraplantar injection of carrageenan into the right hind paw led to a marked accumulation of infiltrating
inflammatory cells and increased myeloperoxidase activity. Both parameters were significantly decreased by orally
given micronized PEA (PEA-m; 10 mg/kg) or ultramicronized PEA (PEA-um; 10 mg/kg), but not nonmicronized
PeaPure (10 mg/kg). Further, carrageenan-induced paw edema and thermal hyperalgesia were markedly and
significantly reduced by oral treatment with micronized PEA-m and ultramicronized PEA-um at each time point
compared to nonmicronized PeaPure. However, when given by the intraperitoneal route, all PEA formulations
proved effective.
Conclusions: These findings illustrate the superior anti-inflammatory action exerted by orally administered,
micronized PEA-m and ultramicronized PEA-um, versus that of nonmicronized PeaPure, in the rat paw carrageenan
model of inflammatory pain.
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Inflammation is fundamentally a protective cellular re-
sponse aimed at removing injurious stimuli and initiat-
ing the healing process [1]. Nonetheless, there are
settings in which the inflammatory response itself dam-
ages host tissue and causes organ dysfunction, such as
an overly robust acute or subacute inflammatory re-
sponse to pathogens or debris from damaged host cells
[2]. As pointed out by Nathan and Ding [1], the problem
with inflammation is not how often it starts, but how
often it fails to subside. Indeed, nonresolving inflamma-
tion is one of the principal contributors to the medical
burden in industrialized societies. Neuroinflammation
in both the peripheral and central nervous systems plays
an important role in the pathogenesis of chronic pain
[3,4]. Therapeutic targeting of the inflammatory response
thus continues to be an area of intense research activity.
Current approaches to treating inflammation target
enzymes, ion channels, RNAs (antisense oligonucleotides)
and epigenetics (for example, histone modification), among
others. An alternative strategy to inhibiting inflammation
would be, quoting Tabas and Glass [5], “to commandeer
nature’s own anti-inflammatory mechanisms to induce a
‘dominant’ program of resolution” Science, p. 7. Resolution
of inflammation is driven not only by selected cell types
but also by the secretion or extracellular formation of
soluble products [1]. Resolution may fail if expression of
these factors is delayed or reduced. Such agents may in-
clude cytokines, a protease inhibitor, gaseous signals,
oxygenated and nitrated lipids, a purine and a neurotrans-
mitter [1]. In this context, the existence of peripheral
lipid-mediated signaling molecules provide an intriguing
avenue of investigation. These lipid mediators act to sup-
press the inflammatory process, restore homeostasis in in-
jured tissues and moderate pain sensitivity by regulating
the flow of nociceptive signals to the central nervous
system [6]. One promising family of such molecules is
the N-acylethanolamines, whose principal members are
the endocannabinoid N-arachidonoylethanolamine (anan-
damide) and its congeners N-stearoylethanolamine, N-
oleoylethanolamine and N-palmitoylethanolamine (PEA)
[7]. PEA’s ability to modulate inflammation and pain in
animal studies led to the proposal of this endogenous fatty
acid amide as a component of a complex homeostatic
system controlling the basal threshold of both inflam-
mation and pain. The fact that PEA is produced during
inflammatory conditions supports this role. Further,
data showing selective inhibition of PEA degradation to
be anti-inflammatory points more directly to PEA’s in-
volvement in the control of pain and inflammation. As
an endogenous compound, PEA has no adverse effects
at pharmacological doses while possessing a double thera-
peutic effect (that is, anti-inflammatory and antinocicep-
tive) (see [8,9] for recent reviews).Given their lipidic nature and large particle size in the
native state, molecules such as PEA may have limitations
in terms of solubility and bioavailability. The use of
micronization for dissolution enhancement of poorly
water-soluble drugs is a technique frequently used in
the pharmaceutical field. By application of this technique,
microparticles are produced by reducing large drug crys-
tals down to the micron range (<10 μm) [10-13]. Given
that the dissolution rate of a drug is proportional to its
surface area, major benefits of microcrystal formulations
are enhanced rate of dissolution [14] and reduced variabil-
ity of drug absorption when orally administered [15].
Carrageenan-induced inflammation in the rat paw repre-
sents a classical model of edema formation and hyperalge-
sia [16] that has been extensively used in the development
of anti-inflammatory drugs. In the present study, we
evaluated the effects of different PEA formulations, both
nonmicronized and micronized/ultramicronized, adminis-
tered orally or parenterally in the carageenan model. The
results demonstrate that micronized/ultramicronized PEA
has a significantly improved anti-inflammatory and anti-
hyperalgesic profile compared to nonmicronized PEA
when given by the oral route.
Methods
Materials
Unless otherwise stated, all compounds used in this study
were purchased from Sigma-Aldrich (Poole, UK). PEA
was obtained from the following sources: Epitech Group
(Saccolongo, Italy), Tocris Bioscience (Bristol, UK),
Cayman Chemical (Ann Arbor, MI, USA), JP Russell
Science (Nicosia, Cyprus), LJ Pharma (Belpasso, Italy) and
GalSor (Montella, Italy). All solutions used for in vivo
infusion were prepared using nonpyrogenic saline (0.9%
wt/vol NaCl; Baxter Healthcare, Thetford, UK).
Animals
The study was carried out using male Sprague-Dawley
rats (200 to 230 g; Harlan, Nossan, Italy). Food and
water were available ad libitum. The study was approved
by the University of Messina Review Board for the care
of animals. Animal care was in compliance with Italian
regulations on the protection of animals used for experi-
mental and other scientific purposes (DM116192) as well
as with the relevant European Economic Community
(EEC) regulations (OJ of EC L 358/1 12/18/1986).
Micronization/ultramicronization of palmitoylethanolamide
PEA was subjected to the air-jet milling technique, in
which a coarse powder is slowly fed into a jet-mill appa-
ratus endowed with a chamber of 300 mm in diameter
that operates with “spiral technology” driven by com-
pressed air. The high number of collisions that occur
between particles as a result of the high level of
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sub-micron-sized crystals [17].
Particle size distribution
Particle size distribution (PSD) was measured by dynamic
light scattering using a Mastersizer 3000 equipped with a
wet dispersion unit (Malvern Instruments, Malvern, UK).
Particles were dispersed in water with the aid of an in-line
sonication probe for rapid agglomerate dispersion.
Palmitoylethanolamide microparticle morphology
The morphology of PEA microparticles was assessed
with a model LEO 1525 scanning electron field emission
microscope (Carl Zeiss SMT AG, Oberkochen, Germany).
Particles were dispersed onto a carbon tab attached to an
aluminum stub (Agar Scientific, Stansted, UK) and then
coated with gold/palladium (250 Å layer thickness) using
a model 108 A sputter coater (Agar Scientific).
High-performance liquid chromatography
The purity of the PEA preparations was determined by
high-performance liquid chromatography (HPLC). PEA
content was also determined and compared to commer-
cially available PEA formulations. Analysis was carried
out using a model 1260 Infinity HPLC System equipped
with a degasser, a binary pump, an automatic liquid
sampler injector, an ultraviolet diode array detector, a
thermostatted column compartment and a thermostatic
module (all from Agilent Technologies, Santa Clara,
CA, USA). The column used was a Zorbax SB-C18
(5 μm, 150 × 4.6 mm; Agilent Technologies). The run-
ning conditions were as follows: column temperature
set at 40°C; absorbance measured at 205 nm; eluent
solution was an 85:15 mix of acetonitrile/(10 mM
ammonium acetate/methanol (2:1 vol/vol)); flow rate of
1.0 ml/min; and injection volume of 10 μl. PEA reten-
tion time was approximately 5.2 minutes. Calibration
was carried out using two different standard solutions,
each prepared from a weighed amount of PEA working
standard: standard 1 = 0.08 mg/ml PEA, standard 2 =
0.60 mg/ml PEA. The sample solution contained a
concentration of about 0.12 mg/ml of equivalent PEA.
Powders recovered from PeaPure and PeaVera (JP
Russell Science Ltd, Netherlands) capsules were ana-
lyzed as such. Other formulations in tablet or granular
form were crushed with a mortar and pestle, weighed,
dissolved in methanol and diluted with the eluent solu-
tion for the HPLC assay.
Experimental groups
Rats were randomly allocated to the following groups:
1. Carrageenan (CAR) + saline: Rats subjected to
CAR-induced paw edema (n = 10)2. CAR + PeaPure (lot 12126A; 10 mg/kg) dissolved in
carboxymethylcellulose (1.5% wt/vol in saline):
Same as CAR + saline group, but administered
(10 mg/kg orally) 30 minutes before CAR (n = 10)
3. CAR +micronized PEA-m (lot 02/10; 10 mg/kg)
dissolved in carboxymethylcellulose (1.5% wt/vol in
saline): Same as CAR + saline group, but administered
(10 mg/kg orally) 30 minutes before CAR (n = 10)
4. CAR + ultramicronized PEA-um (lot 03/08; 10 mg/kg)
dissolved in carboxymethylcellulose (1.5% wt/vol in
saline): Same as CAR + saline group, but administered
(10 mg/kg orally) 30 minutes before CAR (n = 10)
5. CAR + PeaPure (lot 12126A; 10 mg/kg) dissolved in
carboxymethylcellulose (1.5% wt/vol in saline): Same
as CAR + saline group, but administered (10 mg/kg
intraperitoneally) 30 minutes before CAR (n = 10)
6. CAR +micronized PEA-m (lot 02/10; 10 mg/kg)
dissolved in carboxymethylcellulose (1.5% wt/vol in
saline): Same as CAR + saline group, but administered
(10 mg/kg intraperitoneally) 30 minutes before
CAR (n = 10)
7. CAR + ultramicronized PEA-um (lot 03/08; 10 mg/kg)
dissolved in carboxymethylcellulose (1.5% wt/vol in
saline): Same as CAR + saline group, but administered
(10 mg/kg intraperitoneally) 30 minutes before
CAR (n = 10)
The dose and the route of administration of PEA chosen
were based on a those used in a previous study [18]. The
same batches of micronized PEA (PEA-m) and ultra-
micronized PEA (PEA-um) were used for the pharma-
cological and chemical experiments. The sham-operated
group (n = 10) underwent the same surgical procedures as
the CAR group, except that saline or drugs were adminis-
tered instead of carrageenan.
Carrageenan-induced paw edema
Changes in paw volume was measured as previously
described [19]. Briefly, paw volume was measured with a
plethysmometer (Ugo Basile, Comerio, Italy) immediately
prior to the injection of carrageenan and at hourly inter-
vals thereafter for 6 hours. Edema was expressed as the
increase in paw volume in milliliters after carrageenan in-
jection relative to the preinjection value for each animal.
Results are expressed as paw volume change in milliliters.
Behavioral analysis
Behavioral testing was done with the experimenter blinded
to treatment conditions. Hyperalgesic responses to heat
were determined by using the Plantar Test (Hargreaves
method; Ugo Basile) [20] with a cutoff latency of 20 se-
conds to prevent tissue damage. Rats were individually
confined to Plexiglas chambers and allowed to habituate.
A mobile unit consisting of a high-intensity projector bulb
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individual hind paw from beneath the chamber. The with-
drawal latency period of injected paws was determined
with an electronic clock circuit and thermocouple. Results
are expressed as paw withdrawal latencies.Figure 1 Particle size distribution profile of
palmitoylethanolamide. Graph of particle sizes of micronized
palmitoylethanolamide (PEA-m, lot 02/10), ultramicronized PEA
(PEA-um, lot 03/08) and nonmicronized PEA (PeaPure, lot 12126A)
obtained by dynamic light scattering. See Methods for further details.Histological analysis
Paw biopsies were taken 6 hours following intraplantar
injection of carrageenan. Tissue from the hind paw pads
was removed with a scalpel. The tissue slices were fixed in
Dietric solution (14.25% ethanol, 1.85% formaldehyde, 1%
acetic acid) for 1 week at room temperature, dehydrated
by a graded series of ethanol and embedded in Paraplast
(Sherwood Medical). Sections (7-μm thickness) were
deparaffinized with xylene, stained with hematoxylin
and eosin (H&E) and observed with a Dialux 22 Leitz
microscope. Stained sections were scored by two inves-
tigators blinded to the treatment condition. The degree
of inflammation was evaluated according to a previously
described method [21] and assigned a score from 0 to 5,
defined as follows: 0 = no inflammation, 1 = mild inflam-
mation, 2 = mild/moderate inflammation, 3 = moderate
inflammation, 4 =moderate/severe inflammation and 5 =
severe inflammation.Myeloperoxidase activity
Myeloperoxidase (MPO) activity, which is an index of
polymorphonuclear leukocyte accumulation, was deter-
mined as previously described [22]. Paw tissues, collected
at 6 hours after carrageenan induction, were homogenized
in 0.5% hexadecyltrimethylammonium bromide dissolved
in 10 mM potassium phosphate buffer (pH 7.0) and cen-
trifuged for 30 minutes at 20,000 g at 4°C. An aliquot of
the supernatant was allowed to react with a solution of
1.6 mM tetramethylbenzidine/0.1 mM H2O2. The rate of
change in absorbance was measured with a spectropho-
tometer at 650 nm. MPO activity was defined as the
quantity of enzyme degrading 1 mM of peroxide within
1 minute at 37°C and was expressed in units per gram








D10 1.57 μM 1.19 μM 3.19 μM
D50 4.5 μM 2.57 μM 21.1 μM
D90 9.36 μM 4.96 μM 82.9 μM
aPEA-m, Micronized PEA; PEA-um, Ultramicronized PEA. D10, D50 and D90
refer to the percentage of particles below the indicated size according to
ASTM International standards for particle size analysis.Statistical analysis
All values in the figures and text are expressed as mean ±
standard error of the mean (SEM) of n observations. For
in vivo studies, n represents the number of animals
used. In experiments involving histology or immuno-
histochemistry, the figures shown are representative of
at least ten slices analyzed from three experiments
performed on different days. Results were analyzed by
one-way analysis of variance followed by a Bonferroni
post hoc test for multiple comparisons. Significance was
set at P < 0.05.Results
Physicochemical characterization of micronized/
ultramicronized palmitoylethanolamide
Lipidic molecules such as PEA can present challenges in
terms of solubility and bioavailability when administered
orally. Because increasing a drug’s surface area enhances its
rate of dissolution [14] while reducing variability of absorp-
tion [15], we investigated the influence of micronization/
ultramicronization on PEA action in carrageenan-induced
inflammation in the rat paw. Figure 1 shows the PSD pro-
file of micronized and ultramicronized PEA in comparison
to a commercial formulation of nonmicronized PEA. A
clear shift toward lower particle sizes is evident for PEA
upon micronization/ultramicronization. The percentage of
particles below a given size is summarized in Table 1. The
particle size distinction between nonmicronized and
ultramicronized PEA is illustrated morphologically in
the scanning electron microscopic images in Figure 2.
Tables 2 and 3 report, respectively, PEA purity and con-
tent determined by HPLC across a number of currently
available PEA formulations. A considerable degree of
divergence is evident from these analyses, in particular
Figure 2 Scanning electron microscopic images of PEA. Images show ultramicronized palmitoylethanolamide (PEA-um, lot 03/08; top) and
nonmicronized palmitoylethanolamide (PeaPure, lot 12126A; bottom).
Table 2 High-pressure liquid chromatography purity analysis of different palmitoylethanolamide sourcesa
Product PEA-m PEA-um PEA PEA PeaPure 400 mg PeaVera 400 mg
Supplier Epitech Group Epitech Group Cayman Tocris Bioscience JP Russell JP Russell
Lot no. 02/10 03/08 152055-51 3A/151360 12126A 14A09H
Purity claimed >98% >98% >98% >98% 100% 100%
Purity found 100.13% 101.08% 98.97% 101.13% 87.69% 88.60%
aPEA-m, Micronized palmitoylethanolamide; PEA-um, Ultramicronized palmitoylethanolamide. Values exceeding 100% are due to the precision of the analytical
methods used. Assay specification limits are 98% to 102%.
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PeaPure PeaVera Peanase Sinerga
Supplier Epitech Group Epitech Group Epitech Group JP Russell JP Russell LJ Pharma Galsor
Lot no. D09813 D012A4 D067F3 12126A 14A09H SK629 11283
PEA content/dose claimed 300 mg 600 mg 600 mg 400 mg 400 mg 300 mg 150 mg
PEA content found 300.8 mg 611.5 mg 614.5 mg 344.7 mg 347.8 mg 248.5 mg 71.4 mg
aPEA-m, Micronized palmitoylethanolamide; PEA-um, Ultramicronized palmitoylethanolamide. Values exceeding 100% are due to the precision of the analytical
methods used. Assay specification limits are 98% to 102%.
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including PeaPure and PeaVera.
Histological analyses of rat paw tissue
To evaluate histologically the anti-inflammatory effect of
different formulations of PEA, samples of paw tissue from
each experimental group were examined by H&E staining.
No histologic damage was found in sham-operated rats
(Figure 3a and inset a1). In contrast, carrageenan injection
into the right hind paw led to a marked accumulation of
infiltrating inflammatory cells (Figure 3b and inset b1)
compared to control. Inflammatory cell infiltration wasFigure 3 Anti-inflammatory effects of orally administered palmitoylet
carrageenan into the rat hind paw: histological and biochemical anal
staining. (a) Control. (b) Intraplantar injection of carrageenan (CAR) into the
CAR with nonmicronized palmitoylethanolamide (PeaPure) (c); micronized
higher-resolution images of the respective panels. All PEA formulations (10
injection, and all animals were killed 6 hours after CAR injection. (f) Histolo
(MPO) activity in paw tissues from the various treatment groups. Micronize
improvements in both measurements. See Methods for further details. Valusignificantly decreased with treatment of micronized PEA-
m (Figure 3d and inset d1) or ultramicronized PEA-um
(10 mg/kg) (Figure 3e and inset e1). In contrast, treatment
with PeaPure (10 mg/kg) (Figure 3c and inset c1) did not
result in a significant reduction in histological scores of
the carrageenan-treated animals. Histological scores for
the various treatment groups are given in Figure 3f.
Effects of palmitoylethanolamide on myeloperoxidase
activity
The development of histological damage was associated
with increased infiltration of neutrophils, as shown byhanolamide formulations following intraplantar injection of
yses. Histological evaluation was performed by hematoxylin and eosin
rat hind paw. (c) through (e) Intraplantar injection of carrageenan
PEA-m (d) and ultramicronized PEA-um (e). Insets a1 through e1 are
mg/kg for each) were administered orally 30 minutes before CAR
gical scores for the various treatment groups. (g) Myeloperoxidase
d PEA-m and ultramicronized PEA-um produced significant
es are means ± SEM. **P < 0.01 vs sham and *P < 0.05 vs CAR.
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by neutrophils and considered a marker of neutrophilic
infiltration (Figure 3g) [23]. The administration of either
micronized PEA-m or ultramicronized PEA-um (10 mg/kg)
significantly reduced MPO activity (Figure 3g). However,
PeaPure (10 mg/kg) was unable to produce a significant
reduction in neutrophil infiltration in the paw tissues
(Figure 3g).
Effects of palmitoylethanolamide on the time-course of
carrageenan-induced paw edema
Intraplantar injection of carrageenan in rats led to a sig-
nificant and time-dependent increase in paw volume
that was maximal after 5 hours (Figures 4a and 4b). The
carrageenan-induced paw edema was markedly and sig-
nificantly reduced by treatment with micronized PEA-m
and ultramicronized PEA-um at each time point compared
to PeaPure, although there was a trend in this last group
(Figure 4a). Moreover, no significant differences were
observed between treatment groups when the PEA formu-
lations were administered intraperitoneally (Figure 4b).
Effects of palmitoylethanolamide on the time-course of
carrageenan-induced thermal hyperalgesia
Intraplantar injection of carrageenan led to a time-
dependent development of thermal hyperalgesia thatFigure 4 Effects of palmitoylethanolamide formulation on the time co
injection of carrageenan into the rat hind paw. All palmitoylethanolam
intraperitoneally 30 minutes before carrageenan (CAR) injection. Paw edem
ultramicronized PEA-um produced significant improvements in both scores
did not show a significant difference between treatment groups for any of
are means ± SEM. *P < 0.05 and **P < 0.01 vs CAR.peaked at 3 hours and was sustained through 5 hours
(Figures 5a and 5b). Oral administration of ultramicro-
nized PEA-um given 30 minutes before carrageenan
produced a clear and significant inhibition of the deve-
lopment of carrageenan-induced thermal hyperalgesia
(Figure 5a). Similarly, oral treatment with micronized
PEA-m (10 mg/kg) was also efficacious in significantly
attenuating the carrageenan-induced hyperalgesic response.
In contrast, treatment with PeaPure (10 mg/kg) failed to
show a significant reduction, although there was a trend
(Figure 5). Moreover, no significant differences were
observed between treatment groups when the PEA formu-
lations were administered intraperitoneally (Figure 5b).
Discussion
Nonresolving inflammation is a major driver of disease.
Perpetuation of inflammation is an inherent risk, because
inflammation can damage tissue and necrosis can provoke
inflammation. However, when prolonged, inflammation
overrides the bounds of physiological control and eventu-
ally becomes destructive. Inflammation increasingly sur-
faces as a key element in the pathobiology of chronic pain,
neurodegenerative diseases, stroke, spinal cord injury and
possibly even neuropsychiatric disorders [24-28]. It is not
surprising, then, that the inflammatory response is today a
focus of intense research activity. Here we show thaturse of carrageenan-induced paw edema following intraplantar
ide (PEA) formulations (10 mg/kg for each) were administered orally or
a was assessed at the time points indicated. (a) Micronized PEA-m and
in comparison to PeaPure. (b) Intraperitoneal administration of PEA
the PEA formulations tested. See Methods for further details. Values
Figure 5 Effects of palmitoylethanolamide formulation on the time course of carrageenan-induced thermal hyperalgesia following
intraplantar injection of carrageenan in the rat hind paw. All palmitoylethanolamide (PEA) formulations (10 mg/kg for each) were
administered orally or intraperitoneally 30 minutes before carrageenan (CAR) injection. Hyperalgesia was assessed at the time points indicated.
(a) Micronized PEA-m and ultramicronized PEA-um produced significant improvements in both scores in comparison to PeaPure. (b) Intraperitoneal
administration did not show a significant difference between treatment groups. See Methods for further details. Values are means ± SEM.
*P < 0.05 and **P < 0.01 vs CAR.
Impellizzeri et al. Journal of Neuroinflammation 2014, 11:136 Page 8 of 9
http://www.jneuroinflammation.com/content/11/1/136micronized/ultramicronized PEA is orally efficacious in
limiting edema and thermal hyperalgesia in rats receiving
intraplantar injection of carrageenan.
We now know that inflammatory processes may be
counteracted by a program of resolution that includes
the production of lipid mediators able to switch off in-
flammation [29]. One interesting class of such natural
mediators are the N-acylethanolamines, which are com-
posed of a fatty acid and ethanolamine. Fatty acid ethanol-
amine family members include the endocannabinoid
N-arachidonoylethanolamine (anandamide) and its conge-
ners N-stearoylethanolamine, N-oleoylethanolamine and
PEA [7]. PEA may function to maintain cellular homeosta-
sis by acting as a mediator of resolution of inflammatory
processes and by modulating the behaviors of mast cells
and microglia [9], two of the principal cell types in neu-
roinflammatory processes [30,31]. For example, mast cell
amines play a role in the edema induced by zymosan and
carrageenan in rats [32].
Oral delivery of a drug continues to be the most popu-
lar route of administration because of its versatility, ease
of administration and, probably most importantly, patient
compliance. In this context, the physicochemical charac-
teristics of PEA (its lipidic nature and large particle size inthe native state) can become a therapeutic issue in terms
of solubility and bioavailability. Reducing large drug crys-
tals down to the micron or submicron range for dis-
solution enhancement is a technique frequently used in
the pharmaceutical field [10-13], keeping in mind that the
dissolution rate of a drug is proportional to its surface area
[14]. The absorption rate of poorly water-soluble drugs is
especially sensitive to particle size because their bioavail-
ability is dissolution rate–controlled in most cases [15].
Moreover, the rate of absorption of small drug particles
is not influenced by the hydrodynamics in the gastro-
intestinal tract—an important factor in reducing vari-
ability of drug absorption when orally administered
[15,33]. Using the air-jet milling technique, micronized
and ultramicronized formulations of PEA were pro-
duced and shown to possess superior pharmacological
action against carrageenan-induced inflammatory pain.
This was in contrast to a preparation of nonmicronized
PEA (PeaPure), which failed to show efficacy when given
orally in this model.
In the course of our analyses, it became apparent that
there exists a rather wide degree of variability among
available PEA formulations in terms of both purity and
actual content of active ingredients. Investigators should
Impellizzeri et al. Journal of Neuroinflammation 2014, 11:136 Page 9 of 9
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PEA for their experiments.
Conclusions
In this study, we have demonstrated the beneficial effects
of PEA in reducing edema formation and thermal hyper-
algesia in carrageenan-induced inflammation in the rat
paw. These results show the differential effects exerted on
the degree of inflammation by micronized PEA-m and
ultramicronized PEA-um, vs nonmicronized PeaPure, the
latter formulation being ineffective in this model when
given orally.
Abbreviations
CAR: Carrageenan; H&E: Hematoxylin and eosin; HPLC: High-performance
liquid chromatography; MPO: Myeloperoxidase; PEA: Palmitoylethanolamide;
PSD: Particle size distribution; SEM: Standard error of the mean.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EE and CS participated in research design. ID, CM, BG, CR and SR conducted
the experiments. BG, ID and CS performed data analysis. ID, EE and CS
contributed to the writing of the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
The authors would like to thank Giovanni Leotta for his excellent technical
assistance during this study and Valentina Malvagni for editorial assistance
with the manuscript.
Received: 27 June 2014 Accepted: 25 July 2014
References
1. Nathan C, Ding A: Nonresolving inflammation. Cell 2010, 140:871–882.
2. Castellheim A, Brekke OL, Espevik T, Harboe M, Mollnes TE: Innate immune
responses to danger signals in systemic inflammatory response
syndrome and sepsis. Scand J Immunol 2009, 69:479–491.
3. Moalem G, Tracey DJ: Immune and inflammatory mechanisms in
neuropathic pain. Brain Res Rev 2006, 51:240–264.
4. Myers RR, Campana WM, Shubayev VI: The role of neuroinflammation in
neuropathic pain: mechanisms and therapeutic targets. Drug Discov
Today 2006, 11:8–20.
5. Tabas I, Glass CK: Anti-inflammatory therapy in chronic disease:
challenges and opportunities. Science 2013, 166:166–172.
6. Piomelli D, Sasso O: Peripheral gating of pain signals by endogenous
lipid mediators. Nat Neurosci 2014, 17:164–174.
7. Pacher P, Bátkai S, Kunos G: The endocannabinoid system as an emerging
target of pharmacotherapy. Pharmacol Rev 2006, 58:389–462.
8. Petrosino S, Iuvone T, Di Marzo V: N-palmitoylethanolamine: biochemistry
and new therapeutic opportunities. Biochimie 2010, 92:724–727.
9. Skaper SD, Facci L, Giusti P: Glia and mast cells as targets for
palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid
mediator. Mol Neurobiol 2013, 48:340–352.
10. Olusanmi D, Jayawickrama D, Bu D, McGeorge G, Sailes H, Kelleher J,
Gamble JF, Shahd UV, Tobyn M: A control strategy for bioavailability
enhancement by size reduction: effect of micronization conditions on
the bulk, surface and blending characteristics of an active
pharmaceutical ingredient. Powder Technol 2014, 258:222–233.
11. Rasenack N, Müller BW: Micron-size drug particles: common and novel
micronization techniques. Pharm Dev Technol 2004, 9:1–13.
12. Joshi JT: A review on micronization techniques. J Pharmaceutical Sci
Technol 2011, 3:651–681.
13. Chaumeil JC: Micronization: a method of improving the bioavailability of
poorly soluble drugs. Methods Find Exp Clin Pharmacol 1998, 20:211–215.14. Bisrat M, Nyström C: Physicochemical aspects of drug release. VIII.
The relation between particle size and surface specific dissolution rate in
agitated suspensions. Int J Pharm 1988, 47:223–231.
15. Oh DM, Curl RL, Yong CS, Amidon GL: Effect of micronization on the
extent of drug absorption from suspensions in humans. Arch Pharm Res
1995, 18:427–433.
16. Winter CA, Risley EA, Nuss GW: Carrageenan-induced edema in hind paw
of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med
1962, 111:544–547.
17. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E:
A new co-ultramicronized composite including palmitoylethanolamide
and luteolin to prevent neuroinflammation in spinal cord injury.
J Neuroinflammation 2013, 10:91.
18. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G: Antiinflammatory
action of endocannabinoid palmitoylethanolamide and the synthetic
cannabinoid nabilone in a model of acute inflammation in the rat. Br J
Pharmacol 2002, 135:181–187.
19. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT,
Currie MG: Nitric oxide: a key mediator in the early and late phase of
carrageenan-induced rat paw inflammation. Br J Pharmacol 1996,
118:829–838.
20. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive
method for measuring thermal nociception in cutaneous hyperalgesia.
Pain 1988, 32:77–88.
21. Bang JS, da Oh H, Choi HM, Sur BJ, Lim SJ, Kim JY, Yang HI, Yoo MC,
Hahm DH, Kim KS: Anti-inflammatory and antiarthritic effects of piperine
in human interleukin 1β-stimulated fibroblast-like synoviocytes and in
rat arthritis models. Arthritis Res Ther 2009, 11:R49.
22. Cuzzocrea S, Mazzon E, Esposito E, Muia C, Abdelrahman M, Di Paola R,
Crisafulli C, Bramanti P, Thiemermann C: Glycogen synthase kinase-3β
inhibition attenuates the development of ischaemia/reperfusion injury
of the gut. Intensive Care Med 2007, 33:880–893.
23. Finley A, Chen Z, Esposito E, Cuzzocrea S, Sabbadini R, Salvemini D:
Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-
dependent mechanism. PLoS One 2013, 8:e55255.
24. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S,
Pepeu G, Casamenti F: β-Amyloid-induced inflammation and cholinergic
hypofunction in the rat brain in vivo: involvement of the p38MAPK
pathway. Neurobiol Dis 2002, 11:257–274.
25. Dauer W, Przedborski S: Parkinson’s disease: mechanisms and models.
Neuron 2003, 39:889–909.
26. Tenorio G, Kulkarni A, Kerr BJ: Resident glial cell activation in response to
perispinal inflammation leads to acute changes in nociceptive
sensitivity: implications for the generation of neuropathic pain.
Pain 2013, 154:71–81.
27. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O: Neuroinflammation
and psychiatric illness. J Neuroinflammation 2013, 10:43.
28. Iadecola C, Anrather J: The immunology of stroke: from mechanisms to
translation. Nat Med 2011, 17:796–808.
29. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP: The resolution of
inflammation. Nat Rev Immunol 2013, 13:59–66.
30. Skaper SD, Giusti P, Facci L: Microglia and mast cells: two tracks on the
road to neuroinflammation. FASEB J 2012, 26:3103–3117.
31. Skaper SD, Facci L, Giusti P: Mast cells, glia and neuroinflammation:
partners in crime? Immunology 2014, 141:314–327.
32. Damas J, Remacle-Volon G: Mast cell amines and the oedema induced by
zymosan and carrageenans in rats. Eur J Pharmacol 1986, 121:367–376.
33. Scholz A, Abrahamsson B, Diebold SM, Kostewicz E, Polentarutti BI,
Ungell AL, Dressmann JB: Influence of hydrodynamics and particle size on
the absorption of felodipine in Labradors. Pharm Res 2002, 19:42–47.
doi:10.1186/s12974-014-0136-0
Cite this article as: Impellizzeri et al.: Micronized/ultramicronized
palmitoylethanolamide displays superior oral efficacy compared to
nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
Journal of Neuroinflammation 2014 11:136.
